The clinical effect and safety of the combination treatment of lamivudine and adefovir dipivoxil in decompeusated hepatitis B cirrhosis
10.3760/cma.j.issn.1673-4904.2011.19.009
- VernacularTitle:拉米夫定联合阿德福韦酯治疗乙型肝炎失代偿期肝硬化的临床疗效及安全性分析
- Author:
Lefeng DONG
;
Baokun BU
;
Yanfeng YIN
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Liver cirrhosis;
Lamivudine;
Adeforvir dipivoxil
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(19):27-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effect and complication of the combination treatment of lamivudine and adeforvir dipivoxil in decompeasated hepatitis B cirrhosis. Methods Eighty-six cases of decompensated hepatitis B cirrhosis were divided into the observation group and the control group with 43 eases each by random digits table. The control group was treated with routine treatment and lamivudine, and the observation group was added with adefovir dipivoxil on the base of the treatment in the control group. The clinical effect after 12 months' treatment was evaluated. Results After 12 months'treatment, the level of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), albumin ( ALB ) and Child-Pugh grade had significant improvement than that before the treatment in two groups(P < 0.05 ), and in the observation group they improved more obvious (P <0.05). The frequence of seroconversion of HBeAg/HBeAb and HBV DNA in the observation group was higher than that in the control group [86.05%(37/43) vs. 65.12%(28/43),79.07% (34/43) vs. 55.81%(24/43)], and the difference between the two groups was significant (P < 0.05 ). Seven cases of times complications happened in the control group and 8 cases of times complications happened in the observation group and the difference between the two groups was not significant (P > 0.05 ). Conclusion The effect of lamivudine and adefovir dipivoxil in the treatment of decompensated hepatitis B cirrhosis is superior to the only lamivudine.
